Loading...

Stanton Glantz, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address530 Parnassus Avenue, Library
San Francisco CA 94143
Phone415-476-3893
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    American Cancer Society2009Luther Terry Distinguished Career in Tobacco Control
    American Heart Association2006Award of Meritorious Achievement
    2005Elected to Institute of Medicine
    American Society of Preventive Oncology2005Joseph Cullen Memorial Award
    Robert Wood Johnson Foundation2000  - 2003Innovators in Substance Abuse Prevention
    1997UCSF Chancellor's Award for Public Service
    Society of Professional Journalists1996James Madison Freedom of Information Award
    1996Alton Ochsner Award of Special Recognition
    Newsweek1995100 Newsmakers of 1995
    1969  - 1972NSF Graduate Fellowship
    1960Eagle Scout

    Collapse Overview 
    Collapse Overview
    RESEARCH INTERESTS: Dr. Glantz, the Truth Initiative Distinguished Professor of Tobacco Control, conducts research on a wide range of topics ranging from the health effects of secondhand smoke (with particular emphasis on the cardiovascular system) to the efficacy of different tobacco control policies. As the tobacco landscape has changed, Dr. Glantz' work has expanded to include e-cigarettes and marijuana, both of which are expanding the tobacco epidemic.

    Dr. Glantz conducts research on a wide range of issues ranging from the effects of secondhand smoke on the heart through the reductions in heart attacks observed when smokefree policies are enacted, to how the tobacco industry fights tobacco control programs. His research on the effects of secondhand smoke on blood and blood vessels has helped explain why, in terms of heart disease, the effects of secondhand smoke are nearly as large as smoking. Consistent with what would be expected from the biology of secondhand smoke, he demonstrated a large and rapid reduction in the number of people admitted to the hospital with heart attacks in Helena, Montana, after that community made all workplaces and public places smokefree. His work in this area was identified as one of the “top research advances for 2005" by the American Heart Association. He was one of the first people to argue that controlling youth access to tobacco products was not an effective tobacco control strategy and to identify the importance of young adults (not just teens) as targets for the tobacco industry and efforts at smoking cessation and tobacco use prevention.

    He is a globally recognized expert on e-cigarettes and is applying his understanding of the tobacco industry to the emerging marijuana industry as well as the sugar industry.

    Dr. Glantz is Principal Investigator for the $20 million 5 year Tobacco Centers of Regulatory Science (TCORS) that was funded in September 2013 as part of a first-of-its-kind tobacco science regulatory program by the U.S. Food and Drug Administration and the National Institutes of Health. The overarching theme of this Center is the development of improved models to inform tobacco product regulatory strategies that integrate 1) economic impacts of tobacco use on health costs, 2) risk perceptions, perceived acceptability, consumer responses to pro-tobacco marketing and anti-tobacco messages and other social determinants of tobacco use, and 3) rapid changes in risk due to tobacco use and secondhand smoke exposure as manifest in cardiovascular and pulmonary dysfunction.

    He is author or coauthor of numerous publications related to secondhand smoke and tobacco control, as well as many papers on cardiovascular function and biostatistics. He has written several books, including the widely used Primer of Biostatistics (which has been translated into Japanese, French, Russian, German, Italian, Japanese and Spanish, and Primer of Applied Regression and Analysis of Variance). In total, he is the author of 5 books and nearly 400 scientific papers, including the first major review (published in Circulation) which identified involuntary smoking as a cause of heart disease and the landmark July 19, 1995 issue of JAMA on the Brown and Williamson documents, which showed that the tobacco industry knew nicotine was addictive and that smoking caused cancer 40 years ago. This publication was followed up with his book, The Cigarette Papers, which has played a key role in the ongoing litigation surrounding the tobacco industry. His book Tobacco Wars: Inside the California Battles chronicles the last quarter century of battles against the tobacco industry in California. He also wrote Tobacco: Biology and Politics for high school students and The Uninvited Guest, a story about secondhand smoke, for second graders, and Bad Acts, which tells the inside story of the US Department of Justices' massive racketeering lawsuit against the tobacco industry. He ran the successful TobaccoScam project that helped break the historic alliance between the tobacco and hospitality industries. He is now running an educational project, SmokeFreeMovies.ucsf.edu, which is working to end use of movies to promote tobacco.

    Working with the UCSF Library, he has taken the lead in making 90 million pages of previously secret tobacco industry documents available to the entire world via the internet through the UCSF Truth Tobacco Industry Documents Library. This effort has help create a whole new area of scientific investigation based on tobacco industry documents.

    Dr. Glantz is Director of the UCSF Center for Tobacco Control Research and Education, Co-Leader of the Helen Diller Familiy Comprehensive Cancer Center Tobacco Program and a member of the Cardiovascular Research Institute and Philip R. Lee Instiute for Healh Policy Studies.

    He served for 10 years as an Associate Editor of the Journal of the American College of Cardiology and is a member of the California State Scientific Review Panel on Toxic Air Contaminants. He was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2005.

    He has traveled widely and lectured on scientific and policy issues related to clean indoor air, smoking in the movies, and effective tobacco control strategies. His work has attracted considerable attention from the tobacco industry, which has sued the University of California (unsuccessfully) twice in an effort to stop Prof. Glantz' work.


    Collapse Research 
    Collapse Research Activities and Funding
    Improved Models to Inform Tobacco Product Regulation
    NIH/NCI P50CA180890Sep 19, 2013 - Aug 31, 2018
    Role: Principal Investigator
    Postdoctoral training in tobacco control
    NIH/NCI R25CA113710Jul 1, 2006 - Jun 30, 2016
    Role: Principal Investigator
    Analysis of Tobacco Industry Documents
    NIH/NCI R01CA087472Jul 6, 2000 - Jul 31, 2019
    Role: Principal Investigator
    Effect of Tobacco Advocacy at the State Level
    NIH/NIDA R01DA043950Jul 1, 1994 - Jun 30, 2021
    Role: Principal Investigator
    Effect of Tobacco Advocacy at the State Level
    NIH/NCI R01CA061021Jul 1, 1994 - Jul 31, 2016
    Role: Principal Investigator
    CVRI ANIMAL CINERADIOGRAPHY SYSTEM
    NIH/NCRR S10RR003355Jun 1, 1987 - Nov 30, 1988
    Role: Principal Investigator
    CARDIAC MECHANICS
    NIH/NHLBI R01HL025869Jul 1, 1980 - Jun 30, 1999
    Role: Principal Investigator
    MYOCARDIAL ISCHEMIA
    NIH P01HL025847Jun 1, 1980 - Dec 31, 1999
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barry RA, Glantz S. Marijuana Regulatory Frameworks in Four US States: An Analysis Against a Public Health Standard. Am J Public Health. 2018 Jul; 108(7):914-923. PMID: 29874509.
      View in: PubMed
    2. Watkins SL, Glantz S, Chaffee BW. Noncigarette Tobacco Products-Gateway or Diversion?-Reply. JAMA Pediatr. 2018 Jun 04. PMID: 29868756.
      View in: PubMed
    3. van der Eijk Y, Bialous SA, Glantz S. The Tobacco Industry and Children's Rights. Pediatrics. 2018 May; 141(5). PMID: 29712762.
      View in: PubMed
    4. Egbe CO, Bialous SA, Glantz S. FCTC Implementation in Nigeria: Lessons for Low and Middle-Income Countries. Nicotine Tob Res. 2018 Apr 06. PMID: 29660032.
      View in: PubMed
    5. Lempert LK, Glantz S. Tobacco Industry Promotional Strategies Targeting American Indians/Alaska Natives and Exploiting Tribal Sovereignty. Nicotine Tob Res. 2018 Mar 12. PMID: 29546392.
      View in: PubMed
    6. Chaffee BW, Watkins SL, Glantz S. Electronic Cigarette Use and Progression From Experimentation to Established Smoking. Pediatrics. 2018 Apr; 141(4). PMID: 29507167.
      View in: PubMed
    7. Glantz S, Gardiner P. Local Movement to Ban Menthol Tobacco Products as a Result of Federal Inaction. JAMA Intern Med. 2018 Mar 05. PMID: 29507930.
      View in: PubMed
    8. Popova L, Thrul J, Glantz S. Effects of Large Cigarette Warning Labels on Smokers' Expected Longevity. Am J Health Behav. 2018 Mar 01; 42(2):85-92. PMID: 29458517.
      View in: PubMed
    9. Orenstein DG, Glantz S. Regulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control. J Psychoactive Drugs. 2018 Jan-Mar; 50(1):19-32. PMID: 29438634.
      View in: PubMed
    10. Kulik MC, Lisha NE, Glantz S. E-cigarettes Associated With Depressed Smoking Cessation: A Cross-sectional Study of 28 European Union Countries. Am J Prev Med. 2018 Apr; 54(4):603-609. PMID: 29449132.
      View in: PubMed
    11. Dutra LM, Glantz S, Arrazola RA, King BA. Impact of E-Cigarette Minimum Legal Sale Age Laws on Current Cigarette Smoking. J Adolesc Health. 2018 Feb 03. PMID: 29422436.
      View in: PubMed
    12. Dutra LM, Glantz S. Thirty-day smoking in adolescence is a strong predictor of smoking in young adulthood. Prev Med. 2018 Apr; 109:17-21. PMID: 29366819.
      View in: PubMed
    13. Watkins SL, Glantz S, Chaffee BW. Association of Noncigarette Tobacco Product Use With Future Cigarette Smoking Among Youth in the Population Assessment of Tobacco and Health (PATH) Study, 2013-2015. JAMA Pediatr. 2018 Feb 01; 172(2):181-187. PMID: 29297010.
      View in: PubMed
    14. Bialous SA, Glantz S. The Challenges of Monitoring Illicit Trade Should Not Obscure the Success of Tobacco Tax Policy. Am J Public Health. 2018 Feb; 108(2):161-163. PMID: 29320293.
      View in: PubMed
    15. Jawad M, Lee JT, Glantz S, Millett C. Price elasticity of demand of non-cigarette tobacco products: a systematic review and meta-analysis. Tob Control. 2018 Jan 23. PMID: 29363611.
      View in: PubMed
    16. Glantz S, Bareham DW. E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications. Annu Rev Public Health. 2018 Apr 01; 39:215-235. PMID: 29323609.
      View in: PubMed
    17. Glantz S, Halpern-Felsher B, Springer ML. Marijuana, Secondhand Smoke, and Social Acceptability. JAMA Intern Med. 2018 Jan 01; 178(1):13-14. PMID: 29159409.
      View in: PubMed
    18. Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A. The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer. Health Aff (Millwood). 2018 Jan; 37(1):54-61. PMID: 29309234.
      View in: PubMed
    19. van der Eijk Y, Glantz S. Tobacco industry attempts to frame smoking as a 'disability' under the 1990 Americans with Disabilities Act. PLoS One. 2017; 12(11):e0188188. PMID: 29176829.
      View in: PubMed
    20. Kearns CE, Apollonio D, Glantz S. Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer: An historical analysis of internal documents. PLoS Biol. 2017 Nov; 15(11):e2003460. PMID: 29161267.
      View in: PubMed
    21. Velicer C, St Helen G, Glantz S. Tobacco papers and tobacco industry ties in regulatory toxicology and pharmacology. J Public Health Policy. 2018 Feb; 39(1):34-48. PMID: 29116189.
      View in: PubMed
    22. Yao T, Max W, Sung HY, Glantz S, Goldberg RL, Wang JB, Wang Y, Lightwood J, Cataldo J. Relationship between spending on electronic cigarettes, 30-day use, and disease symptoms among current adult cigarette smokers in the U.S. PLoS One. 2017; 12(11):e0187399. PMID: 29112988.
      View in: PubMed
    23. van der Eijk Y, McDaniel PA, Glantz S, Bialous SA. United Nations Global Compact: an 'Inroad' into the UN and reputation boost for the tobacco industry. Tob Control. 2017 Nov 02. PMID: 29097589.
      View in: PubMed
    24. Kulik MC, Glantz S. Softening Among U.S. Smokers With Psychological Distress: More Quit Attempts and Lower Consumption as Smoking Drops. Am J Prev Med. 2017 Dec; 53(6):810-817. PMID: 29029966.
      View in: PubMed
    25. Cho HJ, Dutra LM, Glantz S. Differences in adolescent e-cigarette and cigarette prevalence in two policy environments: South Korea and the United States. Nicotine Tob Res. 2017 Sep 05. PMID: 29059418.
      View in: PubMed
    26. Uang R, Crosbie E, Glantz S. Tobacco control law implementation in a middle-income country: Transnational tobacco control network overcoming tobacco industry opposition in Colombia. Glob Public Health. 2017 Aug 17; 1-15. PMID: 28816610.
      View in: PubMed
    27. Apollonio D, Glantz S. Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us". Am J Public Health. 2017 Oct; 107(10):1636-1642. PMID: 28817320.
      View in: PubMed
    28. Tynan MA, Polansky JR, Titus K, Atayeva R, Glantz S. Tobacco Use in Top-Grossing Movies - United States, 2010-2016. MMWR Morb Mortal Wkly Rep. 2017 Jul 07; 66(26):681-686. PMID: 28683057.
      View in: PubMed
    29. Russo AR, Solis AC, Villanti AC, Wipfli HL, Kern TT, Lawley RK, Collins LK, Abudayyeh HS, Chansky MC, Glantz S, Samet JM, Benjamin EJ. Mentoring for Success in Tobacco Regulatory Science: A Qualitative Study. Tob Regul Sci. 2017 Jul; 3(3):280-292. PMID: 28758143.
      View in: PubMed
    30. Egbe CO, Bialous SA, Glantz S. Avoiding "A Massive Spin-Off Effect in West Africa and Beyond": The Tobacco Industry Stymies Tobacco Control in Nigeria. Nicotine Tob Res. 2017 Jul 01; 19(7):877-887. PMID: 28199720.
      View in: PubMed
    31. Glantz S, Rutherford JD. Here Comes Trouble: A Career as a Tobacco Control Activist. Circulation. 2017 Jun 06; 135(23):2214-2217. PMID: 28584028.
      View in: PubMed
    32. Dutra L, Glantz S. We Agree on the Importance of Contextual and Temporal Accuracy When Studying Novel Tobacco Products. Pediatrics. 2017 05; 139(5). PMID: 28557769.
      View in: PubMed
    33. Jiang N, Gonzalez M, Ling PM, Young-Wolff KC, Glantz S. Smoke-Free Laws and Hazardous Drinking: A Cross-Sectional Study among U.S. Adults. Int J Environ Res Public Health. 2017 04 13; 14(4). PMID: 28406443.
      View in: PubMed
    34. Crosbie E, Sosa P, Glantz S. Defending strong tobacco packaging and labelling regulations in Uruguay: transnational tobacco control network versus Philip Morris International. Tob Control. 2018 Mar; 27(2):185-194. PMID: 28336521.
      View in: PubMed
    35. Uang R, Crosbie E, Glantz S. Smokefree implementation in Colombia: Monitoring, outside funding, and business support. Salud Publica Mex. 2017 Mar-Apr; 59(2):128-136. PMID: 28562713.
      View in: PubMed
    36. Dutra LM, Glantz S, Lisha NE, Song AV. Beyond experimentation: Five trajectories of cigarette smoking in a longitudinal sample of youth. PLoS One. 2017; 12(2):e0171808. PMID: 28182748.
      View in: PubMed
    37. Dutra LM, Glantz S. E-cigarettes and National Adolescent Cigarette Use: 2004-2014. Pediatrics. 2017 Feb; 139(2). PMID: 28115540.
      View in: PubMed
    38. Fallin-Bennett A, Roditis M, Glantz S. The carrot and the stick? Strategies to improve compliance with college campus tobacco policies. J Am Coll Health. 2017 Feb-Mar; 65(2):122-130. PMID: 27869568.
      View in: PubMed
    39. Dutra LM, Grana R, Glantz S. Philip Morris research on precursors to the modern e-cigarette since 1990. Tob Control. 2017 Dec; 26(e2):e97-e105. PMID: 27852893.
      View in: PubMed
    40. Kearns CE, Schmidt LA, Glantz S. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med. 2016 Nov 01; 176(11):1680-1685. PMID: 27617709.
      View in: PubMed
    41. Glantz S. Need for Examination of Broader Range of Risks When Predicting the Effects of New Tobacco Products. Nicotine Tob Res. 2017 Feb; 19(2):266-267. PMID: 28082476.
      View in: PubMed
    42. Barry RA, Glantz S. A Public Health Framework for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry. PLoS Med. 2016 Sep; 13(9):e1002131. PMID: 27676176.
      View in: PubMed
    43. Cox E, Barry RA, Glantz S. E-cigarette Policymaking by Local and State Governments: 2009-2014. Milbank Q. 2016 09; 94(3):520-96. PMID: 27620685.
      View in: PubMed
    44. Lempert LK, Yerger V, Glantz S. Letter by Lempert et al Regarding Article, "Menthol and Nonmenthol Cigarette Smoking: All-Cause Deaths, Cardiovascular Disease Deaths, and Other Causes of Death Among Blacks and Whites". Circulation. 2016 Aug 30; 134(9):e119-20. PMID: 27572884.
      View in: PubMed
    45. Hopkinson NS, Millett C, Glantz S, Arnott D, McNeill A. UK government should fund stop smoking media campaigns not give tax breaks to films with smoking imagery. Addiction. 2016 Nov; 111(11):2066-2067. PMID: 27363590.
      View in: PubMed
    46. Hiilamo H, Glantz S. FCTC followed by accelerated implementation of tobacco advertising bans. Tob Control. 2017 Jul; 26(4):428-433. PMID: 27471111.
      View in: PubMed
    47. Wang X, Derakhshandeh R, Liu J, Narayan S, Nabavizadeh P, Le S, Danforth OM, Pinnamaneni K, Rodriguez HJ, Luu E, Sievers RE, Schick SF, Glantz S, Springer ML. One Minute of Marijuana Secondhand Smoke Exposure Substantially Impairs Vascular Endothelial Function. J Am Heart Assoc. 2016 Jul 27; 5(8). PMID: 27464788.
      View in: PubMed
    48. Lempert LK, Glantz S. Packaging colour research by tobacco companies: the pack as a product characteristic. Tob Control. 2017 05; 26(3):307-315. PMID: 27255118.
      View in: PubMed
    49. Yeh JS, Bullen C, Glantz S. CLINICAL DECISIONS. E-Cigarettes and Smoking Cessation. N Engl J Med. 2016 Jun 02; 374(22):2172-4. PMID: 27248625.
      View in: PubMed
    50. Neeley EE, Glantz S. RJ Reynolds has not published a negative randomised clinical trial of Camel Snus for smoking cessation. Tob Control. 2017 05; 26(3):357-358. PMID: 27207852.
      View in: PubMed
    51. Apollonio DE, Glantz S. Minimum Ages of Legal Access for Tobacco in the United States From 1863 to 2015. Am J Public Health. 2016 Jul; 106(7):1200-7. PMID: 27196658; PMCID: PMC4902755.
    52. Lightwood J, Glantz S. Smoking Behavior and Healthcare Expenditure in the United States, 1992-2009: Panel Data Estimates. PLoS Med. 2016 05; 13(5):e1002020. PMID: 27163933.
      View in: PubMed
    53. Lempert LK, Glantz S. Implications of Tobacco Industry Research on Packaging Colors for Designing Health Warning Labels. Nicotine Tob Res. 2016 09; 18(9):1910-4. PMID: 27146637; PMCID: PMC4978986 [Available on 09/01/17].
    54. Kalkhoran S, Glantz S. E-cigarettes and smoking cessation - Authors' reply. Lancet Respir Med. 2016 06; 4(6):e26-7. PMID: 27133215.
      View in: PubMed
    55. Gendall P, Hoek J, Edwards R, Glantz S. Effect of Exposure to Smoking in Movies on Young Adult Smoking in New Zealand. PLoS One. 2016; 11(3):e0148692. PMID: 26960189; PMCID: PMC4784919.
    56. Crosbie E, Sosa P, Glantz S. The importance of continued engagement during the implementation phase of tobacco control policies in a middle-income country: the case of Costa Rica. Tob Control. 2017 01; 26(1):60-68. PMID: 26856614.
      View in: PubMed
    57. Kalkhoran S, Glantz S. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016 Feb; 4(2):116-28. PMID: 26776875.
      View in: PubMed
    58. Crosbie E, Sosa P, Glantz S. Costa Rica's implementation of the Framework Convention on Tobacco Control: Overcoming decades of industry dominance. Salud Publica Mex. 2016 Jan-Feb; 58(1):62-70. PMID: 26879509; PMCID: PMC4758506.
    59. Liu J, Wang X, Narayan S, Glantz S, Schick SF, Springer ML. Impairment of Endothelial Function by Little Cigar Secondhand Smoke. Tob Regul Sci. 2016 Jan 01; 2(1):56-63. PMID: 26753171.
      View in: PubMed
    60. Velicer C, Glantz S. Hiding in the Shadows: Philip Morris and the Use of Third Parties to Oppose Ingredient Disclosure Regulations. PLoS One. 2015; 10(12):e0142032. PMID: 26717245; PMCID: PMC4696670.
    61. Cheng KW, Liu F, Gonzalez M, Glantz S. The Effects of Workplace Clean Indoor Air Law Coverage on Workers' Smoking-Related Outcomes. Health Econ. 2017 Feb; 26(2):226-242. PMID: 26639369.
      View in: PubMed
    62. Uang R, Hiilamo H, Glantz S. Accelerated Adoption of Smoke-Free Laws After Ratification of the World Health Organization Framework Convention on Tobacco Control. Am J Public Health. 2016 Jan; 106(1):166-71. PMID: 26562125; PMCID: PMC4689638 [Available on 01/01/17].
    63. Popova L, Linde BD, Bursac Z, Talcott GW, Modayil MV, Little MA, Ling PM, Glantz S, Klesges RC. Testing antismoking messages for Air Force trainees. Tob Control. 2016 11; 25(6):656-663. PMID: 26482786.
      View in: PubMed
    64. Jiang N, Gonzalez M, Ling PM, Glantz S. Relationship of Smokefree Laws and Alcohol Use with Light and Intermittent Smoking and Quit Attempts among US Adults and Alcohol Users. PLoS One. 2015; 10(10):e0137023. PMID: 26445314.
      View in: PubMed
    65. Kalkhoran S, Glantz S. Modeling the Health Effects of Expanding e-Cigarette Sales in the United States and United Kingdom: A Monte Carlo Analysis. JAMA Intern Med. 2015 Oct; 175(10):1671-80. PMID: 26322924; PMCID: PMC4594196 [Available on 10/01/16].
    66. Song AV, Dutra LM, Neilands TB, Glantz S. Association of Smoke-Free Laws With Lower Percentages of New and Current Smokers Among Adolescents and Young Adults: An 11-Year Longitudinal Study. JAMA Pediatr. 2015 Sep; 169(9):e152285. PMID: 26348866; PMCID: PMC4577051.
    67. Dixit S, Pletcher MJ, Vittinghoff E, Imburgia K, Maguire C, Whitman IR, Glantz S, Olgin JE, Marcus GM. Secondhand smoke and atrial fibrillation: Data from the Health eHeart Study. Heart Rhythm. 2016 Jan; 13(1):3-9. PMID: 26340844.
      View in: PubMed
    68. Fulmer EB, Neilands TB, Dube SR, Kuiper NM, Arrazola RA, Glantz S. Protobacco Media Exposure and Youth Susceptibility to Smoking Cigarettes, Cigarette Experimentation, and Current Tobacco Use among US Youth. PLoS One. 2015; 10(8):e0134734. PMID: 26308217; PMCID: PMC4550466.
    69. Velicer C, Aguinaga-Bialous S, Glantz S. Tobacco companies' efforts to undermine ingredient disclosure: the Massachusetts benchmark study. Tob Control. 2016 09; 25(5):575-83. PMID: 26292701.
      View in: PubMed
    70. Kulik MC, Glantz S. The smoking population in the USA and EU is softening not hardening. Tob Control. 2016 07; 25(4):470-5. PMID: 26108654.
      View in: PubMed
    71. Fallin A, Glantz S. Tobacco-control policies in tobacco-growing states: where tobacco was king. Milbank Q. 2015 Jun; 93(2):319-58. PMID: 26044632; PMCID: PMC4462880.
    72. Kalkhoran S, Sebrié EM, Sandoya E, Glantz S. Effect of Uruguay's National 100% Smokefree Law on Emergency Visits for Bronchospasm. Am J Prev Med. 2015 Jul; 49(1):85-8. PMID: 25997906; PMCID: PMC4476915.
    73. Stevens D, Glantz S. Tobacco documents reveal questionable professional recertification by industry menthol expert. Tob Control. 2016 May; 25(3):364. PMID: 25967941; PMCID: PMC4643428 [Available on 05/01/17].
    74. Kearns CE, Glantz S, Schmidt LA. Sugar industry influence on the scientific agenda of the National Institute of Dental Research's 1971 National Caries Program: a historical analysis of internal documents. PLoS Med. 2015 Mar; 12(3):e1001798. PMID: 25756179; PMCID: PMC4355299.
    75. Grana R, Benowitz N, Glantz S. Response to letter regarding article, "Electronic cigarettes: a scientific review". Circulation. 2015 Feb 10; 131(6):e342. PMID: 25815391.
      View in: PubMed
    76. Song AV, Glantz S. Assessing tobacco regulation: moving beyond economists. Tob Control. 2015 Mar; 24(2):123-4. PMID: 25564284; PMCID: PMC4336827.
    77. Benowitz NL, Gan Q, Goniewicz ML, Lu W, Xu J, Li X, Jacob P, Glantz S. Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers. Tob Control. 2015 Dec; 24(e4):e258-63. PMID: 25535294.
      View in: PubMed
    78. Fallin A, Roditis M, Glantz S. Association of campus tobacco policies with secondhand smoke exposure, intention to smoke on campus, and attitudes about outdoor smoking restrictions. Am J Public Health. 2015 Jun; 105(6):1098-100. PMID: 25521901; PMCID: PMC4431121.
    79. Lempert LK, Grana R, Glantz S. The importance of product definitions in US e-cigarette laws and regulations. Tob Control. 2016 Apr; 25(e1):e44-51. PMID: 25512432; PMCID: PMC4466213 [Available on 04/01/17].
    80. McKee M, Chapman S, Daube M, Glantz S. The debate on electronic cigarettes. Lancet. 2014 Dec 13; 384(9960):2107. PMID: 25497194.
      View in: PubMed
    81. Roditis ML, Wang D, Glantz S, Fallin A. Evaluating California campus tobacco policies using the American College Health Association guidelines and the Institutional Grammar Tool. J Am Coll Health. 2015; 63(1):57-67. PMID: 25257333; PMCID: PMC4268277.
    82. Hiilamo H, Glantz S. Implementation of effective cigarette health warning labels among low and middle income countries: state capacity, path-dependency and tobacco industry activity. Soc Sci Med. 2015 Jan; 124:241-5. PMID: 25462428; PMCID: PMC4276461.
    83. Hiilamo H, Glantz S. Old wine in new bottles: tobacco industry's submission to European Commission tobacco product directive public consultation. Health Policy. 2015 Jan; 119(1):57-65. PMID: 25467283; PMCID: PMC4453831.
    84. Dutra LM, Glantz S. High international electronic cigarette use among never smoker adolescents. J Adolesc Health. 2014 Nov; 55(5):595-7. PMID: 25344030.
      View in: PubMed
    85. Kostygina G, Glantz S, Ling PM. Tobacco industry use of flavours to recruit new users of little cigars and cigarillos. Tob Control. 2016 Jan; 25(1):66-74. PMID: 25354674; PMCID: PMC4414663 [Available on 01/01/17].
    86. Yao T, Jiang N, Grana R, Ling PM, Glantz S. A content analysis of electronic cigarette manufacturer websites in China. Tob Control. 2016 Mar; 25(2):188-94. PMID: 25335902; PMCID: PMC4405407 [Available on 03/01/17].
    87. Crosbie E, Gonzalez M, Glantz S. Crosbie et Al. Respond. Am J Public Health. 2014 Dec; 104(12):e5. PMID: 25320883.
      View in: PubMed
    88. Mamudu HM, Dadkar S, Veeranki SP, He Y, Barnes R, Glantz S. Multiple streams approach to tobacco control policymaking in a tobacco-growing state. J Community Health. 2014 Aug; 39(4):633-45. PMID: 24370600; PMCID: PMC4074267.
    89. Dutra LM, Glantz S. Youth tobacco use and electronic cigarettes--reply. JAMA Pediatr. 2014 Aug; 168(8):776-7. PMID: 25090297.
      View in: PubMed
    90. Crosbie E, Gonzalez M, Glantz S. Health preemption behind closed doors: trade agreements and fast-track authority. Am J Public Health. 2014 Sep; 104(9):e7-e13. PMID: 25033124; PMCID: PMC4151932.
    91. Dutra LM, Glantz S. Electronic cigarettes and conventional cigarette use among U.S. adolescents: a cross-sectional study. JAMA Pediatr. 2014 Jul; 168(7):610-7. PMID: 24604023; PMCID: PMC4142115.
    92. Sankaran S, Hiilamo H, Glantz S. Implementation of graphic health warning labels on tobacco products in India: the interplay between the cigarette and the bidi industries. Tob Control. 2015 Nov; 24(6):547-55. PMID: 24950697; PMCID: PMC4272673 [Available on 11/01/16].
    93. Velicer C, Lempert LK, Glantz S. Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation. Tob Control. 2015 Sep; 24(5):469-80. PMID: 24920577; PMCID: PMC4263698.
    94. Barry RA, Hiilamo H, Glantz S. Waiting for the opportune moment: the tobacco industry and marijuana legalization. Milbank Q. 2014 Jun; 92(2):207-42. PMID: 24890245; PMCID: PMC4089369.
    95. Grana R, Benowitz N, Glantz S. E-cigarettes: a scientific review. Circulation. 2014 May 13; 129(19):1972-86. PMID: 24821826; PMCID: PMC4018182.
    96. Grana RA, Ling PM, Benowitz N, Glantz S. Electronic cigarettes. Cardiology patient page. Circulation. 2014 May 13; 129(19):e490-2. PMID: 24821830; PMCID: PMC4074376.
    97. Kalkhoran S, Glantz S. Smoke-free policies: cleaning the air with money to spare. Lancet. 2014 May 03; 383(9928):1526-8. PMID: 24680632.
      View in: PubMed
    98. Laposata E, Kennedy AP, Glantz S. When tobacco targets direct democracy. J Health Polit Policy Law. 2014 Jun; 39(3):537-64. PMID: 24603083; PMCID: PMC4040295.
    99. Gonzalez M, Sanders-Jackson A, Glantz S. Association of strong smoke-free laws with dentists' advice to quit smoking, 2006-2007. Am J Public Health. 2014 Apr; 104(4):e88-94. PMID: 24524506; PMCID: PMC4025725.
    100. Ling PM, Lee YO, Hong J, Neilands TB, Jordan JW, Glantz S. Social branding to decrease smoking among young adults in bars. Am J Public Health. 2014 Apr; 104(4):751-60. PMID: 24524502; PMCID: PMC4025707.
    101. Brown-Johnson CG, England LJ, Glantz S, Ling PM. Tobacco industry marketing to low socioeconomic status women in the U.S.A. Tob Control. 2014 Nov; 23(e2):e139-46. PMID: 24449249; PMCID: PMC4105326.
    102. Glantz S, Johnson KC. The surgeon general report on smoking and health 50 years later: breast cancer and the cost of increasing caution. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):37-46. PMID: 24420985.
      View in: PubMed
    103. Song AV, Brown P, Glantz S. When health policy and empirical evidence collide: the case of cigarette package warning labels and economic consumer surplus. Am J Public Health. 2014 Feb; 104(2):e42-51. PMID: 24328661; PMCID: PMC3905322.
    104. Pinnamaneni K, Sievers RE, Sharma R, Selchau AM, Gutierrez G, Nordsieck EJ, Su R, An S, Chen Q, Wang X, Derakhshandeh R, Aschbacher K, Heiss C, Glantz S, Schick SF, Springer ML. Brief exposure to secondhand smoke reversibly impairs endothelial vasodilatory function. Nicotine Tob Res. 2014 May; 16(5):584-90. PMID: 24302638; PMCID: PMC3977486.
    105. Nazar GP, Lee JT, Glantz S, Arora M, Pearce N, Millett C. Association between being employed in a smoke-free workplace and living in a smoke-free home: evidence from 15 low and middle income countries. Prev Med. 2014 Feb; 59:47-53. PMID: 24287123.
      View in: PubMed
    106. Lee S, Grana RA, Glantz S. Electronic cigarette use among Korean adolescents: a cross-sectional study of market penetration, dual use, and relationship to quit attempts and former smoking. J Adolesc Health. 2014 Jun; 54(6):684-90. PMID: 24274973.
      View in: PubMed
    107. Apollonio DE, Glantz S, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5. PMID: 24581055; PMCID: PMC4071941.
    108. Cheng KW, Okechukwu CA, McMillen R, Glantz S. Association between clean indoor air laws and voluntary smokefree rules in homes and cars. Tob Control. 2015 Mar; 24(2):168-74. PMID: 24114562; PMCID: PMC3983176.
    109. Sanders-Jackson AN, Song AV, Hiilamo H, Glantz S. Effect of the Framework Convention on Tobacco Control and voluntary industry health warning labels on passage of mandated cigarette warning labels from 1965 to 2012: transition probability and event history analyses. Am J Public Health. 2013 Nov; 103(11):2041-7. PMID: 24028248; PMCID: PMC3795937.
    110. Glantz S, Gibbs E. Changes in ambulance calls after implementation of a smoke-free law and its extension to casinos. Circulation. 2013 Aug 20; 128(8):811-3. PMID: 23918257; PMCID: PMC3781209.
    111. Polansky J, Glantz S. Debate over tobacco and film ratings should be evidence-based. N Z Med J. 2013 Jul 12; 126(1378):88. PMID: 24045321.
      View in: PubMed
    112. Basu S, Glantz S, Bitton A, Millett C. The effect of tobacco control measures during a period of rising cardiovascular disease risk in India: a mathematical model of myocardial infarction and stroke. PLoS Med. 2013; 10(7):e1001480. PMID: 23874160; PMCID: PMC3706364.
    113. Glantz S. Israel is failing to protect its citizens from secondhand smoke: underestimating public support. Isr J Health Policy Res. 2013 Jun 27; 2(1):24. PMID: 23805997; PMCID: PMC3702447.
    114. Sanders-Jackson A, Gonzalez M, Zerbe B, Song AV, Glantz S. The pattern of indoor smoking restriction law transitions, 1970-2009: laws are sticky. Am J Public Health. 2013 Aug; 103(8):e44-51. PMID: 23763408; PMCID: PMC3727646.
    115. Tan CE, Kyriss T, Glantz S. Tobacco company efforts to influence the Food and Drug Administration-commissioned Institute of Medicine report clearing the smoke: an analysis of documents released through litigation. PLoS Med. 2013; 10(5):e1001450. PMID: 23723740; PMCID: PMC3665841.
    116. Sebrié EM, Sandoya E, Bianco E, Hyland A, Cummings KM, Glantz S. Hospital admissions for acute myocardial infarction before and after implementation of a comprehensive smoke-free policy in Uruguay: experience through 2010. Tob Control. 2014 Nov; 23(6):471-2. PMID: 25324157; PMCID: PMC4358818.
    117. Sterling K, Berg CJ, Thomas AN, Glantz S, Ahluwalia JS. Factors associated with small cigar use among college students. Am J Health Behav. 2013 May; 37(3):325-33. PMID: 23985179; PMCID: PMC3757522.
    118. Lee JT, Agrawal S, Basu S, Glantz S, Millett C. Association between smoke-free workplace and second-hand smoke exposure at home in India. Tob Control. 2014 Jul; 23(4):308-12. PMID: 23525121.
      View in: PubMed
    119. Gonzalez M, Sanders-Jackson A, Song AV, Cheng KW, Glantz S. Strong smoke-free law coverage in the United States by race/ethnicity: 2000-2009. Am J Public Health. 2013 May; 103(5):e62-6. PMID: 23488507; PMCID: PMC3698815.
    120. Lightwood J, Glantz S. The effect of the California tobacco control program on smoking prevalence, cigarette consumption, and healthcare costs: 1989-2008. PLoS One. 2013; 8(2):e47145. PMID: 23418411; PMCID: PMC3572143.
    121. Fallin A, Grana R, Glantz S. 'To quarterback behind the scenes, third-party efforts': the tobacco industry and the Tea Party. Tob Control. 2014 Jul; 23(4):322-31. PMID: 23396417; PMCID: PMC3740007.
    122. Millett C, Lee JT, Laverty AA, Glantz S, Majeed A. Hospital admissions for childhood asthma after smoke-free legislation in England. Pediatrics. 2013 Feb; 131(2):e495-501. PMID: 23339216; PMCID: PMC4528337.
    123. Glantz S. Slaying the Jabberwock: the link between strong smokefree policies and drops in acute myocardial infarctions survives the funnel plot. Int J Cardiol. 2013 Sep 30; 168(2):1534. PMID: 23270745.
      View in: PubMed
    124. Crosbie E, Glantz S. Tobacco industry argues domestic trademark laws and international treaties preclude cigarette health warning labels, despite consistent legal advice that the argument is invalid. Tob Control. 2014 May; 23(3):e7. PMID: 23179728; PMCID: PMC3725199.
    125. Laposata E, Barnes R, Glantz S. Tobacco Industry Influence on the American Law Institute's Restatements of Torts and Implications for Its Conflict of Interest Policies. Iowa Law Rev. 2012 Nov; 98(1):1-68. PMID: 23633723.
      View in: PubMed
    126. Tan CE, Glantz S. Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. Circulation. 2012 Oct 30; 126(18):2177-83. PMID: 23109514; PMCID: PMC3501404.
    127. Hiilamo H, Crosbie E, Glantz S. The evolution of health warning labels on cigarette packs: the role of precedents, and tobacco industry strategies to block diffusion. Tob Control. 2014 Jan; 23(1):e2. PMID: 23092884; PMCID: PMC3725195.
    128. Tan CE, Glantz S. SMOKEFREE AIR: AN IMPORTANT STRATEGY TO REDUCING HEART ATTACKS AROUND THE WORLD. Glob Heart. 2012 Jul; 7(2):189-191. PMID: 23710433.
      View in: PubMed
    129. Frey PF, Ganz P, Hsue PY, Benowitz NL, Glantz S, Balmes JR, Schick SF. The exposure-dependent effects of aged secondhand smoke on endothelial function. J Am Coll Cardiol. 2012 May 22; 59(21):1908-13. PMID: 22595411.
      View in: PubMed
    130. Sebrié EM, Schoj V, Travers MJ, McGaw B, Glantz S. Smokefree policies in Latin America and the Caribbean: making progress. Int J Environ Res Public Health. 2012 05; 9(5):1954-70. PMID: 22754484; PMCID: PMC3386598.
    131. Schane RE, Prochaska JJ, Glantz S. Counseling nondaily smokers about secondhand smoke as a cessation message: a pilot randomized trial. Nicotine Tob Res. 2013 Feb; 15(2):334-42. PMID: 22592447; PMCID: PMC3545714.
    132. Lee S, Glantz S. South Korea: 'KT&G Sangsang Univ.' employs education for marketing. Tob Control. 2012 Jul; 21(4):445-6. PMID: 22467711; PMCID: PMC3383443.
    133. Kennedy A, Sullivan S, Hendlin Y, Barnes R, Glantz S. Strong tobacco control program requirements and secure funding are not enough: lessons from Florida. Am J Public Health. 2012 May; 102(5):807-17. PMID: 22420813; PMCID: PMC3325324.
    134. Glantz S. Pinocchio shows how to end the tobacco epidemic. Tob Control. 2012 Mar; 21(2):296-7; discussion 297-8. PMID: 22345273.
      View in: PubMed
    135. Lee S, Ling PM, Glantz S. The vector of the tobacco epidemic: tobacco industry practices in low and middle-income countries. Cancer Causes Control. 2012 Mar; 23 Suppl 1:117-29. PMID: 22370696; PMCID: PMC3332051.
    136. Sebrié EM, Sandoya E, Hyland A, Bianco E, Glantz S, Cummings KM. Hospital admissions for acute myocardial infarction before and after implementation of a comprehensive smoke-free policy in Uruguay. Tob Control. 2013 May; 22(e1):e16-20. PMID: 22337557; PMCID: PMC3374906.
    137. Crosbie E, Sebrié EM, Glantz S. Tobacco industry success in Costa Rica: the importance of FCTC article 5.3. Salud Publica Mex. 2012 Jan-Feb; 54(1):28-38. PMID: 22286826; PMCID: PMC3296364.
    138. Glantz S, Iaccopucci A, Titus K, Polansky JR. Smoking in top-grossing US movies, 2011. Prev Chronic Dis. 2012; 9:120170. PMID: 23017248; PMCID: PMC3475526.
    139. Hiilamo H, Glantz S. Local Nordic tobacco interests collaborated with multinational companies to maintain a united front and undermine tobacco control policies. Tob Control. 2013 Mar; 22(2):154-64. PMID: 22199013; PMCID: PMC3346886.
    140. Gonzalez M, Ling PM, Glantz S. Planting trees without leaving home: tobacco company direct-to-consumer CSR efforts. Tob Control. 2012 May; 21(3):363-5. PMID: 22193045; PMCID: PMC3600898.
    141. Wertz MS, Kyriss T, Paranjape S, Glantz S. The toxic effects of cigarette additives. Philip Morris' project mix reconsidered: an analysis of documents released through litigation. PLoS Med. 2011 Dec; 8(12):e1001145. PMID: 22205885; PMCID: PMC3243707.
    142. Millett C, Hanewinkel R, Britton J, Florek E, Faggiano F, Ness A, McKee M, Polansky JR, Glantz S. European governments should stop subsidizing films with tobacco imagery. Eur J Public Health. 2012 Apr; 22(2):167-8. PMID: 22179095.
      View in: PubMed
    143. Arnott D, Berteletti F, Britton J, Cardone A, Clancy L, Craig L, Fong GT, Glantz S, Joossens L, Rudolphie MT, Rutgers MR, Smith SC, Stam H, West R, Willemsen MC. Can the Dutch Government really be abandoning smokers to their fate? Lancet. 2012 Jan 14; 379(9811):121-2. PMID: 22169107.
      View in: PubMed
    144. Gonzalez M, Glantz S. Failure of policy regarding smoke-free bars in the Netherlands. Eur J Public Health. 2013 Feb; 23(1):139-45. PMID: 22143826; PMCID: PMC3553585.
    145. Cheng KW, Glantz S, Lightwood JM. Association between smokefree laws and voluntary smokefree-home rules. Am J Prev Med. 2011 Dec; 41(6):566-72. PMID: 22099232; PMCID: PMC3222862.
    146. Weeks SG, Glantz S, De Marco T, Rosen AB, Fleischmann KE. Secondhand smoke exposure and quality of life in patients with heart failure. Arch Intern Med. 2011 Nov 28; 171(21):1887-93. PMID: 22123794.
      View in: PubMed
    147. Prochaska JJ, Benowitz NL, Glantz S, Hudmon KS, Grossman W. Cardiology Rx for Change: improving clinical attention to tobacco use and secondhand smoke exposure in cardiology. Clin Cardiol. 2011 Dec; 34(12):738-43. PMID: 21987417.
      View in: PubMed
    148. Basu S, Stuckler D, Bitton A, Glantz S. Projected effects of tobacco smoking on worldwide tuberculosis control: mathematical modelling analysis. BMJ. 2011 Oct 04; 343:d5506. PMID: 21972295; PMCID: PMC3186817.
    149. Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2012 Mar 31; 379(9822):1269-71. PMID: 21963004; PMCID: PMC3260384.
    150. Glantz S, Polansky JR. Movies with smoking make less money. Tob Control. 2012 Nov; 21(6):569-71. PMID: 21948805.
      View in: PubMed
    151. Mamudu HM, Gonzalez M, Glantz S. The nature, scope, and development of the global tobacco control epistemic community. Am J Public Health. 2011 Nov; 101(11):2044-54. PMID: 21940926; PMCID: PMC3207640.
    152. Millett C, Polansky JR, Glantz S. Government inaction on ratings and government subsidies to the US film industry help promote youth smoking. PLoS Med. 2011 Aug; 8(8):e1001077. PMID: 21886486; PMCID: PMC3160342.
    153. Lee JT, Glantz S, Millett C. Effect of smoke-free legislation on adult smoking behaviour in England in the 18 months following implementation. PLoS One. 2011; 6(6):e20933. PMID: 21698295; PMCID: PMC3115957.
    154. Grana RA, Glantz S, Ling PM. Electronic nicotine delivery systems in the hands of Hollywood. Tob Control. 2011 Nov; 20(6):425-6. PMID: 21659450; PMCID: PMC3184316.
    155. Gonzalez M, Green LW, Glantz S. Through tobacco industry eyes: civil society and the FCTC process from Philip Morris and British American Tobacco's perspectives. Tob Control. 2012 Jul; 21(4):e1. PMID: 21636611; PMCID: PMC3188334.
    156. Salgado MV, Glantz S. Direct disease-inducing effects of menthol through the eyes of tobacco companies. Tob Control. 2011 May; 20 Suppl 2:ii44-8. PMID: 21504931.
      View in: PubMed
    157. Lee YO, Glantz S. Menthol: putting the pieces together. Tob Control. 2011 May; 20 Suppl 2:ii1-7. PMID: 21504926; PMCID: PMC3085012.
    158. Otañez M, Glantz S. Social responsibility in tobacco production? Tobacco companies' use of green supply chains to obscure the real costs of tobacco farming. Tob Control. 2011 Nov; 20(6):403-11. PMID: 21504915; PMCID: PMC3155738.
    159. Millett C, Lee JT, Gibbons DC, Glantz S. Increasing the age for the legal purchase of tobacco in England: impacts on socio-economic disparities in youth smoking. Thorax. 2011 Oct; 66(10):862-5. PMID: 21502102; PMCID: PMC3158837.
    160. Glantz S, Ling PM. Misleading conclusions from Altria researchers about population health effects of dual use. Nicotine Tob Res. 2011 Apr; 13(4):296; author reply 297. PMID: 21350043; PMCID: PMC4031571.
    161. Chu A, Jiang N, Glantz S. Transnational tobacco industry promotion of the cigarette gifting custom in China. Tob Control. 2011 Jul; 20(4):e3. PMID: 21282136; PMCID: PMC3124594.
    162. Lightwood J, Glantz S. Effect of the Arizona tobacco control program on cigarette consumption and healthcare expenditures. Soc Sci Med. 2011 Jan; 72(2):166-72. PMID: 21168248; PMCID: PMC3603372.
    163. Crosbie E, Sebrié EM, Glantz S. Strong advocacy led to successful implementation of smokefree Mexico City. Tob Control. 2011 Jan; 20(1):64-72. PMID: 21059606; PMCID: PMC3089444.
    164. Gan Q, Glantz S. Relationship between the Chinese tobacco industry and academic institutions in China. Tob Control. 2011 Jan; 20(1):12-9. PMID: 20952560; PMCID: PMC3084598.
    165. Mamudu HM, Hammond R, Glantz S. International trade versus public health during the FCTC negotiations, 1999-2003. Tob Control. 2011 Jan; 20(1):e3. PMID: 20943828; PMCID: PMC3089441.
    166. Sullivan S, Glantz S. Local smoke-free ordinances are passing in tobacco-growing states. Am J Public Health. 2010 Nov; 100(11):2013-4; author reply 2014. PMID: 20864731; PMCID: PMC2951956.
    167. Sullivan S, Glantz S. The changing role of agriculture in tobacco control policymaking: a South Carolina case study. Soc Sci Med. 2010 Oct; 71(8):1527-34. PMID: 20828907; PMCID: PMC2943232.
    168. Heiss C, Jahn S, Taylor M, Real WM, Angeli FS, Wong ML, Amabile N, Prasad M, Rassaf T, Ottaviani JI, Mihardja S, Keen CL, Springer ML, Boyle A, Grossman W, Glantz S, Schroeter H, Yeghiazarians Y. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol. 2010 Jul 13; 56(3):218-24. PMID: 20620742.
      View in: PubMed
    169. Glantz S. Commentary on Hanewinkel et al. (2010): Anti-smoking advertisments vaccinate movie viewers against effects of on-screen smoking. Addiction. 2010 Jul; 105(7):1278-9. PMID: 20642511.
      View in: PubMed
    170. Mejia AB, Ling PM, Glantz S. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control. 2010 Aug; 19(4):297-305. PMID: 20581427; PMCID: PMC3102305.
    171. Hendlin Y, Anderson SJ, Glantz S. 'Acceptable rebellion': marketing hipster aesthetics to sell Camel cigarettes in the US. Tob Control. 2010 Jun; 19(3):213-22. PMID: 20501494; PMCID: PMC3088012.
    172. Gan Q, Lu W, Xu J, Li X, Goniewicz M, Benowitz NL, Glantz S. Chinese 'low-tar' cigarettes do not deliver lower levels of nicotine and carcinogens. Tob Control. 2010 Oct; 19(5):374-9. PMID: 20507920; PMCID: PMC2978929.
    173. Millett C, Glantz S. Assigning an '18' rating to movies with tobacco imagery is essential to reduce youth smoking. Thorax. 2010 May; 65(5):377-8. PMID: 20435857.
      View in: PubMed
    174. Cataldo JK, Glantz S. Smoking cessation and Alzheimer's disease: facts, fallacies and promise. Expert Rev Neurother. 2010 May; 10(5):629-31. PMID: 20420482; PMCID: PMC3637838.
    175. Schane RE, Ling PM, Glantz S. Health effects of light and intermittent smoking: a review. Circulation. 2010 Apr 06; 121(13):1518-22. PMID: 20368531; PMCID: PMC2865193.
    176. Shmueli D, Prochaska JJ, Glantz S. Effect of smoking scenes in films on immediate smoking: a randomized controlled study. Am J Prev Med. 2010 Apr; 38(4):351-8. PMID: 20307802; PMCID: PMC2854161.
    177. Anderson SJ, Millett C, Polansky JR, Glantz S. Exposure to smoking in movies among British adolescents 2001-2006. Tob Control. 2010 Jun; 19(3):197-200. PMID: 20197360; PMCID: PMC2989169.
    178. Stanton CR, Chu A, Collin J, Glantz S. Promoting tobacco through the international language of dance music: British American Tobacco and the Ministry of Sound. Eur J Public Health. 2011 Feb; 21(1):21-8. PMID: 20159772; PMCID: PMC3023012.
    179. Cataldo JK, Prochaska JJ, Glantz S. Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis. 2010; 19(2):465-80. PMID: 20110594; PMCID: PMC2906761.
    180. Sebrié EM, Blanco A, Glantz S. Cigarette labeling policies in Latin America and the Caribbean: progress and obstacles. Salud Publica Mex. 2010; 52 Suppl 2:S233-43. PMID: 21243194; PMCID: PMC3090221.
    181. Sebrié EM, Glantz S. Local smoke-free policy development in Santa Fe, Argentina. Tob Control. 2010 Apr; 19(2):110-6. PMID: 19955534; PMCID: PMC2989155.
    182. Gan Q, Yang J, Yang G, Goniewicz M, Benowitz NL, Glantz S. Chinese "herbal" cigarettes are as carcinogenic and addictive as regular cigarettes. Cancer Epidemiol Biomarkers Prev. 2009 Dec; 18(12):3497-501. PMID: 19959701; PMCID: PMC2789338.
    183. Schane RE, Glantz S, Ling PM. Nondaily and social smoking: an increasingly prevalent pattern. Arch Intern Med. 2009 Oct 26; 169(19):1742-4. PMID: 19858429; PMCID: PMC4350771.
    184. Lightwood JM, Glantz S. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation. 2009 Oct 06; 120(14):1373-9. PMID: 19770392; PMCID: PMC2967202.
    185. Otañez MG, Mamudu HM, Glantz S. Tobacco companies' use of developing countries' economic reliance on tobacco to lobby against global tobacco control: the case of Malawi. Am J Public Health. 2009 Oct; 99(10):1759-71. PMID: 19696392; PMCID: PMC2741530.
    186. Schane RE, Glantz S, Ling PM. Social smoking implications for public health, clinical practice, and intervention research. Am J Prev Med. 2009 Aug; 37(2):124-31. PMID: 19589449; PMCID: PMC2771192.
    187. Glantz S, Barnes R, Eubanks SY. Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products. PLoS Med. 2009 Jul; 6(7):e1000118. PMID: 19636359; PMCID: PMC2709428.
    188. Song AV, Glantz S, Halpern-Felsher BL. Perceptions of second-hand smoke risks predict future adolescent smoking initiation. J Adolesc Health. 2009 Dec; 45(6):618-25. PMID: 19931835; PMCID: PMC2814413.
    189. Angeli FS, Shapiro M, Amabile N, Orcino G, Smith CS, Tacy T, Boyle AJ, Chatterjee K, Glantz S, Grossman W, Yeghiazarians Y. Left ventricular remodeling after myocardial infarction: characterization of a swine model on beta-blocker therapy. Comp Med. 2009 Jun; 59(3):272-9. PMID: 19619418; PMCID: PMC2733287.
    190. Glantz S. Limited linkages between secondhand smoke discovery and delivery: more a speed bump than a gap. Am J Prev Med. 2009 Jun; 36(6):555-6. PMID: 19460659; PMCID: PMC2702850.
    191. Otañez MG, Glantz S. Trafficking in tobacco farm culture: Tobacco companies use of video imagery to undermine health policy. Vis Anthropol Rev. 2009 May 01; 25(1):1-24. PMID: 20160936.
      View in: PubMed
    192. Dinno A, Glantz S. Tobacco control policies are egalitarian: a vulnerabilities perspective on clean indoor air laws, cigarette prices, and tobacco use disparities. Soc Sci Med. 2009 Apr; 68(8):1439-47. PMID: 19282078; PMCID: PMC2748432.
    193. Ling PM, Neilands TB, Glantz S. Young adult smoking behavior: a national survey. Am J Prev Med. 2009 May; 36(5):389-394.e2. PMID: 19269128; PMCID: PMC2700137.
    194. Tung GJ, Hendlin YH, Glantz S. Competing initiatives: a new tobacco industry strategy to oppose statewide clean indoor air ballot measures. Am J Public Health. 2009 Mar; 99(3):430-9. PMID: 19150904; PMCID: PMC2642532.
    195. Landman A, Glantz S. Tobacco industry efforts to undermine policy-relevant research. Am J Public Health. 2009 Jan; 99(1):45-58. PMID: 19008508; PMCID: PMC2600597.
    196. Mamudu HM, Hammond R, Glantz S. Tobacco industry attempts to counter the World Bank report Curbing the Epidemic and obstruct the WHO framework convention on tobacco control. Soc Sci Med. 2008 Dec; 67(11):1690-9. PMID: 18950924; PMCID: PMC2662513.
    197. Schane RE, Glantz S. Education on the dangers of passive smoking: a cessation strategy past due. Circulation. 2008 Oct 07; 118(15):1521-3. PMID: 18838572; PMCID: PMC2760983.
    198. Schneider NK, Glantz S. "Nicotine Nazis strike again": a brief analysis of the use of Nazi rhetoric in attacking tobacco control advocacy. Tob Control. 2008 Oct; 17(5):291-6. PMID: 18818222; PMCID: PMC2736555.
    199. Lightwood JM, Dinno A, Glantz S. Effect of the California tobacco control program on personal health care expenditures. PLoS Med. 2008 Aug 26; 5(8):e178. PMID: 18752344; PMCID: PMC2522256.
    200. Song AV, Glantz S. Pushing secondhand smoke and the tobacco industry outside the social norm to reduce adolescent smoking. J Adolesc Health. 2008 Oct; 43(4):315-7. PMID: 18809127; PMCID: PMC2566746.
    201. Mamudu HM, Hammond R, Glantz S. Project Cerberus: tobacco industry strategy to create an alternative to the Framework Convention on Tobacco Control. Am J Public Health. 2008 Sep; 98(9):1630-42. PMID: 18633079; PMCID: PMC2509616.
    202. Glantz S. Meta-analysis of the effects of smokefree laws on acute myocardial infarction: an update. Prev Med. 2008 Oct; 47(4):452-3. PMID: 18602944; PMCID: PMC2927851.
    203. Heiss C, Amabile N, Lee AC, Real WM, Schick SF, Lao D, Wong ML, Jahn S, Angeli FS, Minasi P, Springer ML, Hammond SK, Glantz S, Grossman W, Balmes JR, Yeghiazarians Y. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol. 2008 May 06; 51(18):1760-71. PMID: 18452782.
      View in: PubMed
    204. Alamar BC, Glantz S. Externalities in the Workplace: A Response to a Rejoinder to a Response to a Response to a Paper. Econ J Watch. 2008 May 01; 5(2):169-173. PMID: 19756237.
      View in: PubMed
    205. Slinker BK, Glantz S. Multiple linear regression: accounting for multiple simultaneous determinants of a continuous dependent variable. Circulation. 2008 Apr 01; 117(13):1732-7. PMID: 18378626.
      View in: PubMed
    206. Landman A, Cortese DK, Glantz S. Tobacco industry sociological programs to influence public beliefs about smoking. Soc Sci Med. 2008 Feb; 66(4):970-81. PMID: 18164524; PMCID: PMC2267871.
    207. Sebrié EM, Schoj V, Glantz S. Smokefree environments in Latin America: on the road to real change? Prev Control. 2008 Jan 01; 3(1):21-35. PMID: 19578527.
      View in: PubMed
    208. Song AV, Ling PM, Neilands TB, Glantz S. Smoking in movies and increased smoking among young adults. Am J Prev Med. 2007 Nov; 33(5):396-403. PMID: 17950405; PMCID: PMC2976714.
    209. Tong EK, Glantz S. Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease. Circulation. 2007 Oct 16; 116(16):1845-54. PMID: 17938301.
      View in: PubMed
    210. Barnes RL, Glantz S. Endotoxins in tobacco smoke: shifting tobacco industry positions. Nicotine Tob Res. 2007 Oct; 9(10):995-1004. PMID: 17852769.
      View in: PubMed
    211. Sebrié EM, Glantz S. "Accommodating" smoke-free policies: tobacco industry's Courtesy of Choice programme in Latin America. Tob Control. 2007 Oct; 16(5):e6. PMID: 17897975; PMCID: PMC2598557.
    212. Schick SF, Glantz S. Concentrations of the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in sidestream cigarette smoke increase after release into indoor air: results from unpublished tobacco industry research. Cancer Epidemiol Biomarkers Prev. 2007 Aug; 16(8):1547-53. PMID: 17684127.
      View in: PubMed
    213. Anderson SJ, Ling PM, Glantz S. Implications of the federal court order banning the terms "light" and "mild": what difference could it make? Tob Control. 2007 Aug; 16(4):275-9. PMID: 17652244; PMCID: PMC2598546.
    214. Otañez MG, Mamudu H, Glantz S. Global leaf companies control the tobacco market in Malawi. Tob Control. 2007 Aug; 16(4):261-9. PMID: 17652242; PMCID: PMC2598545.
    215. Ling PM, Neilands TB, Glantz S. The effect of support for action against the tobacco industry on smoking among young adults. Am J Public Health. 2007 Aug; 97(8):1449-56. PMID: 17600255; PMCID: PMC1931473.
    216. Alamar B, Glantz S. Effect of smoke-free laws on bar value and profits. Am J Public Health. 2007 Aug; 97(8):1400-2. PMID: 17600258; PMCID: PMC1931474.
    217. Sebrié EM, Glantz S. Attempts to undermine tobacco control: tobacco industry "youth smoking prevention" programs to undermine meaningful tobacco control in Latin America. Am J Public Health. 2007 Aug; 97(8):1357-67. PMID: 17600260; PMCID: PMC1931455.
    218. Ibrahim JK, Glantz S. The rise and fall of tobacco control media campaigns, 1967 2006. Am J Public Health. 2007 Aug; 97(8):1383-96. PMID: 17600257; PMCID: PMC1931454.
    219. Schick SF, Glantz S. Old ways, new means: tobacco industry funding of academic and private sector scientists since the Master Settlement Agreement. Tob Control. 2007 Jun; 16(3):157-64. PMID: 17565125; PMCID: PMC2598497.
    220. John RM, Glantz S. It is time to make smokefree environments work in India. Indian J Med Res. 2007 May; 125(5):599-603. PMID: 17642492.
      View in: PubMed
    221. Dinno A, Glantz S. Clean indoor air laws immediately reduce heart attacks. Prev Med. 2007 Jul; 45(1):9-11. PMID: 17499350; PMCID: PMC2693058.
    222. Chen A, Glantz S, Tong E. Asian herbal-tobacco cigarettes: "not medicine but less harmful"? Tob Control. 2007 Apr; 16(2):e3. PMID: 17400933; PMCID: PMC2598477.
    223. Glantz S. Commentary: Assessing the effects of the Scottish Smokefree Law--the placebo effect and the importance of obtaining unbiased data. Int J Epidemiol. 2007 Feb; 36(1):155-6. PMID: 17229833.
      View in: PubMed
    224. Barnes RL, Hammond SK, Glantz S. The tobacco industry's role in the 16 Cities Study of secondhand tobacco smoke: do the data support the stated conclusions? Environ Health Perspect. 2006 Dec; 114(12):1890-7. PMID: 17185281; PMCID: PMC1764165.
    225. Torrijos RM, Glantz S. The US Public Health Service "treating tobacco use and dependence clinical practice guidelines" as a legal standard of care. Tob Control. 2006 Dec; 15(6):447-51. PMID: 17130373; PMCID: PMC2563672.
    226. Schick SF, Schick S, Glantz S. Sidestream cigarette smoke toxicity increases with aging and exposure duration. Tob Control. 2006 Dec; 15(6):424-9. PMID: 17130369; PMCID: PMC2563675.
    227. Barnoya J, Glantz S. Cardiovascular effects of second-hand smoke help explain the benefits of smoke-free legislation on heart disease burden. J Cardiovasc Nurs. 2006 Nov-Dec; 21(6):457-62. PMID: 17293735.
      View in: PubMed
    228. Healton CG, Watson-Stryker ES, Allen JA, Vallone DM, Messeri PA, Graham PR, Stewart AM, Dobbins MD, Glantz S. Televised movie trailers: undermining restrictions on advertising tobacco to youth. Arch Pediatr Adolesc Med. 2006 Sep; 160(9):885-8. PMID: 16953010.
      View in: PubMed
    229. Mandel LL, Bialous SA, Glantz S. Avoiding "truth": tobacco industry promotion of life skills training. J Adolesc Health. 2006 Dec; 39(6):868-79. PMID: 17116518.
      View in: PubMed
    230. Alamar B, Glantz S. Effect of increased social unacceptability of cigarette smoking on reduction in cigarette consumption. Am J Public Health. 2006 Aug; 96(8):1359-63. PMID: 16809588; PMCID: PMC1522108.
    231. Alamar B, Glantz S. Tobacco industry profits from smoking images in the movies. Pediatrics. 2006 Apr; 117(4):1462. PMID: 16585358.
      View in: PubMed
    232. Alamar B, Glantz S. Modeling Addictive Consumption as an Infectious Disease. Contrib Econ Analysis Policy. 2006 Mar 17; 5(1):1-22. PMID: 21339848.
      View in: PubMed
    233. Sebrié E, Glantz S. The tobacco industry in developing countries. BMJ. 2006 Feb 11; 332(7537):313-4. PMID: 16470028; PMCID: PMC1363897.
    234. Ibrahim JK, Glantz S. Tobacco industry litigation strategies to oppose tobacco control media campaigns. Tob Control. 2006 Feb; 15(1):50-8. PMID: 16436406; PMCID: PMC2563618.
    235. Glantz S, Polansky J. Smoking in movies. Chest. 2006 Feb; 129(2):495; author reply 495-6. PMID: 16478874.
      View in: PubMed
    236. Charlesworth A, Glantz S. Tobacco and the movie industry. Clin Occup Environ Med. 2006; 5(1):73-84, ix. PMID: 16446255.
      View in: PubMed
    237. Glantz FK, Glantz S. Protecting Europeans from secondhand smoke: time to act. Eur Heart J. 2006 Feb; 27(4):382-3. PMID: 16339159.
      View in: PubMed
    238. Charlesworth A, Glantz S. Smoking in the movies increases adolescent smoking: a review. Pediatrics. 2005 Dec; 116(6):1516-28. PMID: 16322180.
      View in: PubMed
    239. Barnoya J, Glantz S. The tobacco industry's worldwide ETS consultants project: European and Asian components. Eur J Public Health. 2006 Feb; 16(1):69-77. PMID: 16076855.
      View in: PubMed
    240. Schick S, Glantz S. Scientific analysis of second-hand smoke by the tobacco industry, 1929-1972. Nicotine Tob Res. 2005 Aug; 7(4):591-612. PMID: 16085530.
      View in: PubMed
    241. Barnoya J, Bialous SA, Glantz S. Effective interventions to reduce smoking-induced heart disease around the world: time to act. Circulation. 2005 Jul 26; 112(4):456-8. PMID: 16043657.
      View in: PubMed
    242. Cook DM, Tong EK, Glantz S, Bero LA. The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood). 2005 Jul-Aug; 24(4):994-1004. PMID: 16136637.
      View in: PubMed
    243. Ong MK, Glantz S. Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. Am J Public Health. 2005 Jun; 95(6):969-75. PMID: 15914818; PMCID: PMC1449293.
    244. Barnoya J, Glantz S. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005 May 24; 111(20):2684-98. PMID: 15911719.
      View in: PubMed
    245. Glantz S. Tobacco money at the University of California. Am J Respir Crit Care Med. 2005 May 15; 171(10):1067-9. PMID: 15879426.
      View in: PubMed
    246. Tong EK, England L, Glantz S. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry. Pediatrics. 2005 Mar; 115(3):e356-66. PMID: 15741361.
      View in: PubMed
    247. Glantz S, Mandel LL. Since school-based tobacco prevention programs do not work, what should we do? J Adolesc Health. 2005 Mar; 36(3):157-9. PMID: 15737768.
      View in: PubMed
    248. Bitton A, Neuman MD, Barnoya J, Glantz S. The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest. Lancet. 2005 Feb 5-11; 365(9458):531-40. PMID: 15705463.
      View in: PubMed
    249. S. Glantz.Primer of Biostatistics (6 ed). 2005.
    250. Kunyk D, Freeman B, Glantz S. Health conventions in smoke free places have positive economic impact. BMJ. 2004 Dec 04; 329(7478):1346. PMID: 15576760; PMCID: PMC534895.
    251. Alamar BC, Glantz S. SMOKE-FREE ORDINANCES INCREASE RESTAURANT PROFIT AND VALUE. Contemp Econ Policy. 2004 Oct; 22(4):520-525. PMID: 21637722.
      View in: PubMed
    252. Barnoya J, Glantz S. Association of the California tobacco control program with declines in lung cancer incidence. Cancer Causes Control. 2004 Sep; 15(7):689-95. PMID: 15280627.
      View in: PubMed
    253. Ong MK, Glantz S. Cardiovascular health and economic effects of smoke-free workplaces. Am J Med. 2004 Jul 01; 117(1):32-8. PMID: 15210386.
      View in: PubMed
    254. Barnoya J, Glantz S. Modifiable behavioral factors as causes of death. JAMA. 2004 Jun 23; 291(24):2941-2; author reply 2942-3. PMID: 15213199.
      View in: PubMed
    255. Ling PM, Glantz S. Tobacco industry research on smoking cessation. Recapturing young adults and other recent quitters. J Gen Intern Med. 2004 May; 19(5 Pt 1):419-26. PMID: 15109339; PMCID: PMC1492251.
    256. Sargent RP, Shepard RM, Glantz S. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ. 2004 Apr 24; 328(7446):977-80. PMID: 15066887; PMCID: PMC404491.
    257. Glantz S, Kacirk KW, McCulloch C. Back to the future: Smoking in movies in 2002 compared with 1950 levels. Am J Public Health. 2004 Feb; 94(2):261-3. PMID: 14759939; PMCID: PMC1448240.
    258. Barnoya J, Glantz S. Secondhand smoke and cardiologists: the missing link. Int J Cardiol. 2004 Feb; 93(2-3):331; author reply 333. PMID: 14975576.
      View in: PubMed
    259. Givel M, Glantz S. The "global settlement" with the tobacco industry: 6 years later. Am J Public Health. 2004 Feb; 94(2):218-24. PMID: 14759930; PMCID: PMC1448231.
    260. Barnoya J, Glantz S. Secondhand smoke: the evidence of danger keeps growing. Am J Med. 2004 Feb 01; 116(3):201-2. PMID: 14749167.
      View in: PubMed
    261. Glantz S. Effect of viewing smoking in movies on adolescent smoking initiation: a cohor study. J Pediatr. 2004 Jan; 144(1):137-8. PMID: 14735907.
      View in: PubMed
    262. Zhu BQ, Heeschen C, Sievers RE, Karliner JS, Parmley WW, Glantz S, Cooke JP. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell. 2003 Sep; 4(3):191-6. PMID: 14522253.
      View in: PubMed
    263. Tsoukalas T, Glantz S. The Duluth clean indoor air ordinance: problems and success in fighting the tobacco industry at the local level in the 21st century. Am J Public Health. 2003 Aug; 93(8):1214-21. PMID: 12893598; PMCID: PMC1447940.
    264. Glantz S. Smoking in movies: a major problem and a real solution. Lancet. 2003 Jul 26; 362(9380):258-9. PMID: 12892950.
      View in: PubMed
    265. Barnoya J, Glantz S. The tobacco industry and secondhand smoke: lessons from Central and South America. Ethn Dis. 2003; 13(2 Suppl 2):S88-90. PMID: 13677420.
      View in: PubMed
    266. Barnoya J, Glantz S. Knowledge and use of tobacco among Guatemalan physicians. Cancer Causes Control. 2002 Nov; 13(9):879-81. PMID: 12462553.
      View in: PubMed
    267. Glantz S. Limiting youth access to tobacco: a failed intervention. J Adolesc Health. 2002 Oct; 31(4):301-2. PMID: 12359373.
      View in: PubMed
    268. Fichtenberg CM, Glantz S. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ. 2002 Jul 27; 325(7357):188. PMID: 12142305; PMCID: PMC117445.
    269. Ling PM, Glantz S. Using tobacco-industry marketing research to design more effective tobacco-control campaigns. JAMA. 2002 Jun 12; 287(22):2983-9. PMID: 12052128.
      View in: PubMed
    270. Fichtenberg CM, Glantz S. Youth access interventions do not affect youth smoking. Pediatrics. 2002 Jun; 109(6):1088-92. PMID: 12042547.
      View in: PubMed
    271. Ling PM, Glantz S. Nicotine addiction, young adults, and smoke-free bars. Drug Alcohol Rev. 2002 Jun; 21(2):101-4. PMID: 12188987.
      View in: PubMed
    272. Landman A, Ling PM, Glantz S. Tobacco industry youth smoking prevention programs: protecting the industry and hurting tobacco control. Am J Public Health. 2002 Jun; 92(6):917-30. PMID: 12036777; PMCID: PMC1447482.
    273. Ling PM, Glantz S. Why and how the tobacco industry sells cigarettes to young adults: evidence from industry documents. Am J Public Health. 2002 Jun; 92(6):908-16. PMID: 12036776; PMCID: PMC1447481.
    274. Neuman M, Bitton A, Glantz S. Tobacco industry strategies for influencing European Community tobacco advertising legislation. Lancet. 2002 Apr 13; 359(9314):1323-30. PMID: 11965294.
      View in: PubMed
    275. Glantz S. Air pollution as a cause of heart disease. Time for action. J Am Coll Cardiol. 2002 Mar 20; 39(6):943-5. PMID: 11897433.
      View in: PubMed
    276. Sepe E, Ling PM, Glantz S. Smooth moves: bar and nightclub tobacco promotions that target young adults. Am J Public Health. 2002 Mar; 92(3):414-9. PMID: 11867322; PMCID: PMC1447091.
    277. Zhu BQ, Sievers RE, Browne AE, Hillman RT, Chair K, Lee RJ, Chatterjee K, Glantz S, Parmley WW. The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke. J Renin Angiotensin Aldosterone Syst. 2002 Mar; 3(1):54-60. PMID: 11984749.
      View in: PubMed
    278. Dearlove JV, Glantz S. Boards of Health as venues for clean indoor air policy making. Am J Public Health. 2002 Feb; 92(2):257-65. PMID: 11818302; PMCID: PMC1447053.
    279. Givel MS, Glantz S. State tobacco settlement funds not being spent on vigorous tobacco control efforts. Oncology (Williston Park). 2002 Feb; 16(2):152, 155-7. PMID: 11866133.
      View in: PubMed
    280. Sepe E, Glantz S. Bar and club tobacco promotions in the alternative press: targeting young adults. Am J Public Health. 2002 Jan; 92(1):75-8. PMID: 11772765; PMCID: PMC1447392.
    281. Glantz S. Rate movies with smoking "R". Eff Clin Pract. 2002 Jan-Feb; 5(1):31-4. PMID: 11874194.
      View in: PubMed
    282. S. Glantz, B. Slinker.Primer of Applied Regression and Analysis of Variance (2 ed). 2000.
    283. S. Glantz, E. Balbach.Tobacco War: Inside the California Battles. 2000.
    284. S. Glantz, J. Slade, L. Bero, P. Hanauer, D. Barnes.The Cigarette Papers. 1996.
    285. S. Glantz.Mathematics for Biomedical Applications. 1979.
    Stanton's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _